{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:05:54Z","timestamp":1790334354122,"version":"4.1.0"},"reference-count":114,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Background: Patients with refractory and relapsed acute myeloid leukemia (R\/R AML) face a dismal prognosis. CAR-T therapy has emerged as a potential treatment option. This study assesses the available clinical evidence on CAR-T in R\/R AML, focusing on safety and efficacy outcomes. Methods: We included studies on CAR-T therapy for R\/R AML published from June 2014 to January 2025. Data on patient and disease characteristics, CAR-T constructs, response rates, post-CAR-T allogeneic HSCT (allo-HSCT), and safety outcomes were analyzed. Results: Twenty-five CAR-T clinical trials involving 296 patients were identified. The most frequently targeted antigens were CD33, CD123, and CLL-1, while CD7, CD19, NKG2D, and CD38 were also explored. Responses were heterogeneous and often short-lived when not consolidated with allo-HSCT. Cytokine release syndrome and neurotoxicity were generally low grade and manageable. Prolonged and severe myelosuppression was a frequent limiting toxicity, often requiring allo-HSCT to restore hematopoiesis. Disease progression was the leading cause of death, followed by infections. Conclusions: CAR-T cell therapy may represent a feasible therapeutic strategy, particularly as bridging to allo-HSCT to mitigate myelotoxicity and improve long-term outcomes. Nevertheless, it remains in the early stages of development and faces significant efficacy and safety challenges that must be addressed in future trials to enable the expansion of this promising therapeutic approach for a population with high unmet medical needs.<\/jats:p>","DOI":"10.3390\/curroncol32060322","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T09:22:41Z","timestamp":1748596961000},"page":"322","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CAR-T Cell Therapy for Acute Myeloid Leukemia: Where Do We Stand Now?"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6661-9631","authenticated-orcid":false,"given":"Pilar","family":"Lloret-Madrid","sequence":"first","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6741-971X","authenticated-orcid":false,"given":"Pedro","family":"Chor\u00e3o","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-2578","authenticated-orcid":false,"given":"Manuel","family":"Guerreiro","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Fe (IISLAFE), 46026 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Universitari i Polit\u00e8cnic La Fe, 46026 Valencia, Spain"},{"name":"Department of Medicine, University of Valencia, 46010 Valencia, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"ref_2","unstructured":"(2025, February 03). Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: Acute Myeloid Leukemia (AML). National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage Regimens Using Conventional Chemotherapy Agents for Relapsed\/Refractory Adult AML Patients: A Systematic Literature Review","volume":"97","author":"Sanz","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1200\/JCO.2010.32.8500","article-title":"Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System","volume":"29","author":"Thiede","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of Relapsed Acute Myeloid Leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of Relapsed\/Refractory Acute Myeloid Leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s12185-022-03416-7","article-title":"Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: An Overview of Prevention and Treatment","volume":"116","author":"Kreidieh","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3324\/haematol.2017.168716","article-title":"Outcome after Relapse of Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation: A Retrospective Registry Analysis on 698 Patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation","volume":"103","author":"Schmid","year":"2018","journal-title":"Haematologica"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12185-018-2412-8","article-title":"Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"107","author":"Takami","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Roex, G., Feys, T., Beguin, Y., Kerre, T., Poir\u00e9, X., Lewalle, P., Vandenberghe, P., Bron, D., and Anguille, S. (2020). Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12020194"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hon.3153","article-title":"CAR T-Cell Therapy in Large B Cell Lymphoma","volume":"41","author":"Boardman","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma (CARTITUDE-1): A Phase 1b\/2 Open-Label Study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Damiani, D., and Tiribelli, M. (2024). CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?. Biomedicines, 12.","DOI":"10.3390\/biomedicines12061194"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1097\/HS9.0000000000000937","article-title":"CAR-T in the Treatment of Acute Myeloid Leukemia: Barriers and How to Overcome Them","volume":"7","author":"Vanhooren","year":"2023","journal-title":"HemaSphere"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Canichella, M., Molica, M., Mazzone, C., and de Fabritiis, P. (2024). Chimeric Antigen Receptor T-Cell Therapy in Acute Myeloid Leukemia: State of the Art and Recent Advances. Cancers, 16.","DOI":"10.3390\/cancers16010042"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s40259-021-00477-8","article-title":"CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success","volume":"35","author":"Fiorenza","year":"2021","journal-title":"BioDrugs"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_19","unstructured":"National Institute for Health Research (2025, April 03). PROSPERO: International Prospective Register of Systematic Reviews. University of York. Available online: https:\/\/www.Crd.York.Ac.Uk\/Prospero\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a Web and Mobile App for Systematic Reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"El Achi, H., Dupont, E., Paul, S., and Khoury, J.D. (2020). CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers, 12.","DOI":"10.3390\/cancers12113087"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1002\/cyto.b.21745","article-title":"CD123 Expression Levels in 846 Acute Leukemia Patients Based on Standardized Immunophenotyping","volume":"96","author":"Bras","year":"2019","journal-title":"Cytom. Part B Clin."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and Levels of Cell Surface Expression of CD33 and CD123 in Acute Myeloid Leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","article-title":"Coexpression Profile of Leukemic Stem Cell Markers for Combinatorial Targeted Therapy in AML","volume":"33","author":"Haubner","year":"2019","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1182\/blood-2022-165339","article-title":"CD84: A Novel Target for CAR T-Cell Therapy for Acute Myeloid Leukemia","volume":"140","author":"Santos","year":"2022","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000077554","article-title":"Minimal Residual Disease Studies by Flow Cytometry in Acute Leukemia","volume":"112","author":"Campana","year":"2004","journal-title":"Acta Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-022-03797-7","article-title":"Naturally Selected CD7 CAR-T Therapy without Genetic Editing Demonstrates Significant Antitumour Efficacy against Relapsed and Refractory Acute Myeloid Leukaemia (R\/R-AML)","volume":"20","author":"Lu","year":"2022","journal-title":"J. Transl. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s40164-022-00318-6","article-title":"CD7-Directed CAR T-Cell Therapy: A Potential Immunotherapy Strategy for Relapsed\/Refractory Acute Myeloid Leukemia","volume":"11","author":"Cao","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 Signaling Promotes Blast Stemness and Is a Viable Therapeutic Target in Acute Myeloid Leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J. Exp. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_31","unstructured":"Malavasi, F., and Mehta, K. (2000). CD38 in Hematopoietic Malignancies. Human CD38 and Related Molecules, S. Karger AG."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhong, X., and Ma, H. (2022). Targeting CD38 for Acute Leukemia. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1007783"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of Folate Receptor \u03b2 on Acute Myeloid Leukemia Blasts with Chimeric Antigen Receptor\u2013Expressing T Cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e98561","DOI":"10.1172\/jci.insight.98561","article-title":"Universal Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia","volume":"3","author":"Song","year":"2018","journal-title":"JCI Insight"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1182\/blood-2012-01-404699","article-title":"Overexpression of IL-1 Receptor Accessory Protein in Stem and Progenitor Cells and Outcome Correlation in AML and MDS","volume":"120","author":"Barreyro","year":"2012","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1182\/blood-2012-09-458935","article-title":"Selective Killing of Candidate AML Stem Cells by Antibody Targeting of IL1RAP","volume":"121","author":"Askmyr","year":"2013","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1084\/jem.20180147","article-title":"IL1RAP Potentiates Multiple Oncogenic Signaling Pathways in AML","volume":"215","author":"Mitchell","year":"2018","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1158\/2643-3230.BCD-20-0208","article-title":"NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity","volume":"2","author":"Richards","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-Directed CAR-T Cell Therapy: A Novel Immunotherapy Strategy for Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"10247","DOI":"10.1182\/blood-2022-166790","article-title":"Preclinical Development of a CAR-T Cell Approach Targeting the CD84 Antigen Associated to Pediatric Acute Myeloid Leukemia","volume":"140","author":"Pigazzi","year":"2022","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2883.2","DOI":"10.1182\/blood-2024-203204","article-title":"Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1\/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients with r\/r AML","volume":"144","author":"Subklewe","year":"2024","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2021.04.042","article-title":"CD19-Specific CAR-T Cell Therapy for Relapsed\/Refractory Non-B-Cell Acute Leukaemia with CD19 Antigen Expression","volume":"153","author":"Liu","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"ref_43","first-page":"42","article-title":"Anti-CD19 Chimeric Antigen Receptor Targeting of CD19 + Acute Myeloid Leukemia","volume":"9","author":"Ma","year":"2018","journal-title":"Leuk. Res. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/sj.leu.2401830","article-title":"Expression of CD44 Variant Exons in Acute Myeloid Leukemia Is More Common and More Complex than That Observed in Normal Blood, Bone Marrow or CD34+ Cells","volume":"14","author":"Bendall","year":"2000","journal-title":"Leukemia"},{"key":"ref_45","first-page":"3401","article-title":"A Strong Expression of CD44-6v Correlates With Shorter Survival of Patients With Acute Myeloid Leukemia","volume":"91","author":"Legras","year":"1998","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"5259","DOI":"10.1182\/blood-2018-99-113037","article-title":"Frequency and Clinical Characteristics Associated with Putative CAR Targets ADGRE2, CCR1, CD70, and LILRB2 in Acute Myeloid Leukemia","volume":"132","author":"Shahswar","year":"2018","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","article-title":"Targeting C-Type Lectin-like Molecule-1 for Antibody-Mediated Immunotherapy in Acute Myeloid Leukemia","volume":"95","author":"Zhao","year":"2010","journal-title":"Haematologica"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating Mutation of D835 within the Activation Loop of FLT3 in Human Hematologic Malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The Roles of FLT3 in Hematopoiesis and Leukemia","volume":"100","author":"Gilliland","year":"2002","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Roy, A.G., Robinson, J.M., Sharma, P., Rodriguez-Garcia, A., Poussin, M.A., Nickerson-Nutter, C., and Powell, D.J. (2021). Folate Receptor Beta as a Direct and Indirect Target for Antibody-Based Cancer Immunotherapy. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22115572"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1016\/j.ymthe.2018.08.001","article-title":"A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML","volume":"26","author":"John","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/gt.2010.21","article-title":"Gene-Modified T Cells as Immunotherapy for Multiple Myeloma and Acute Myeloid Leukemia Expressing the Lewis Y Antigen","volume":"17","author":"Peinert","year":"2010","journal-title":"Gene Ther."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.4049\/jimmunol.1200796","article-title":"Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses","volume":"189","author":"Hilpert","year":"2012","journal-title":"J. Immunol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood-2004-07-2585","article-title":"Ligands for Natural Killer Cell\u2013Activating Receptors Are Expressed upon the Maturation of Normal Myelomonocytic Cells but at Low Levels in Acute Myeloid Leukemias","volume":"105","author":"Nowbakht","year":"2005","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1182\/blood.2021013184","article-title":"Siglec-6 CAR T: Magic Bullet for a Moving Target","volume":"138","author":"Ghorashian","year":"2021","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood.2020009192","article-title":"Siglec-6 Is a Novel Target for CAR T-Cell Therapy in Acute Myeloid Leukemia","volume":"138","author":"Jetani","year":"2021","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1535-7163.MCT-20-0155","article-title":"Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells","volume":"20","author":"Lee","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s12253-015-0002-0","article-title":"WT1 Expression in Adult Acute Myeloid Leukemia: Assessing Its Presence, Magnitude and Temporal Changes as Prognostic Factors","volume":"22","author":"Ujj","year":"2016","journal-title":"Pathol. Oncol. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s43042-022-00291-z","article-title":"Wilms Tumor 1 Gene Expression in Acute Myeloid Leukemia: Prognostic Significance and Usefulness in Minimal Residual Disease Monitoring\u2014A Case\u2013Control Study","volume":"23","author":"Donia","year":"2022","journal-title":"Egypt. J. Med. Hum. Genet."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1038\/s41422-022-00721-y","article-title":"Genetically Modified CD7-Targeting Allogeneic CAR-T Cell Therapy with Enhanced Efficacy for Relapsed\/Refractory CD7-Positive Hematological Malignancies: A Phase I Clinical Study","volume":"32","author":"Hu","year":"2022","journal-title":"Cell Res."},{"key":"ref_61","unstructured":"Hu, Y., Zhang, M., Zhao, H., Wei, G., Chang, A.H., and Huang, H. (2023, January 23\u201326). High Safety and Efficacy of Anti-CD7 CAR-T Cells in Treating Relapsed or Refractory CD7+ Acute Myeloid Leukemia: First-in-Human Phase I Study. Proceedings of the 49th EBMT Annual Meeting, Paris, France."},{"key":"ref_62","first-page":"103471","article-title":"Point of Care CD19 Chimeric Antigen Receptor (CAR) T-Cells for Relapsed\/Refractory Acute Myeloid Leukemia (AML) with Aberrant CD19 Antigen Expression","volume":"72","author":"Danylesko","year":"2024","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T Cells for Treatment of Relapsed\/Refractory Acute Myelogenous Leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-Directed Chimeric Antigen Receptor-Modified T Cells in One Patient With Relapsed and Refractory Acute Myeloid Leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"10313","DOI":"10.1182\/blood-2022-169142","article-title":"Phase 1\/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-Cells (CD33CART) for Children and Young Adults with Relapsed\/Refractory AML: Dose-Escalation Results from a Phase I\/II Multicenter Trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6155","DOI":"10.1038\/s41467-024-50485-9","article-title":"C-JUN Overexpressing CAR-T Cells in Acute Myeloid Leukemia: Preclinical Characterization and Phase I Trial","volume":"15","author":"Zuo","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1182\/blood-2024-207659","article-title":"The Safety and Efficacy of CD33 CAR-T Therapy for RR AML after HSCT","volume":"144","author":"Lin","year":"2024","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1182\/blood-2023-177867","article-title":"Updated Results from a Phase I Dose Escalation Study of the Rapidly-Switchable Universal CAR-T Therapy UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"142","author":"Wermke","year":"2023","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R\/R) CD123+ Acute Myeloid Leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood.V130.Suppl_1.811.811","article-title":"Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial","volume":"130","author":"Budde","year":"2017","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4584","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Yao, S., Jianlin, C., Yarong, L., Botao, L., Qinghan, W., Hongliang, F., Lu, Z., Hongmei, N., Pin, W., and Hu, C. (2019). Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG+ AML. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01358"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","article-title":"Characteristics of Anti-CLL1 Based CAR-T Therapy for Children with Relapsed or Refractory Acute Myeloid Leukemia: The Multi-Center Efficacy and Safety Interim Analysis","volume":"36","author":"Zhang","year":"2022","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1186\/s12967-024-05705-7","article-title":"Efficacy and Safety of CAR-T Therapy Targeting CLL1 in Patients with Extramedullary Diseases of Acute Myeloid Leukemia","volume":"22","author":"Zhao","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_76","first-page":"615","article-title":"Successful Application of PD-1 Knockdown CLL-1 CAR-T Therapy in Two AML Patients with Post-Transplant Relapse and Failure of Anti-CD38 CAR-T Cell Treatment","volume":"12","author":"Ma","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Miao, X., Shuai, Y., Han, Y., Zhang, N., Liu, Y., Yao, H., Wang, X., He, G., Chen, D., and Fan, F. (2024). Case Report: Donor-Derived CLL-1 Chimeric Antigen Receptor T-Cell Therapy for Relapsed\/Refractory Acute Myeloid Leukemia Bridging to Allogeneic Hematopoietic Stem Cell Transplantation after Remission. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1389227"},{"key":"ref_78","unstructured":"Liu, F., Cao, Y., Pinz, K., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C.O., and Su, Y. (2020, January 11\u201314). First-In-Human Cll1-Cd33 Compound Car (Ccar) T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia. Proceedings of the 25th EHA Annual Congress, Frankfurt, Germany."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","article-title":"CYAD-01, an Autologous NKG2D-Based CAR T-Cell Therapy, in Relapsed or Refractory Acute Myeloid Leukaemia and Myelodysplastic Syndromes or Multiple Myeloma (THINK): Haematological Cohorts of the Dose Escalation Segment of a Phase 1 Trial","volume":"10","author":"Sallman","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1158\/2326-6066.CIR-18-0307","article-title":"Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML\/MDS and Multiple Myeloma","volume":"7","author":"Baumeister","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1182\/blood-2020-139667","article-title":"First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients","volume":"136","author":"Deeren","year":"2020","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1309\/LG0Q0VXYBETJ4VHE","article-title":"Expression of B Cell-Specific Activator Protein\/PAX5 in Acute Myeloid Leukemia with t(8;21)(Q22;Q22)","volume":"126","author":"Valbuena","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.ymthe.2018.10.001","article-title":"CD7 CAR T Cells for the Therapy of Acute Myeloid Leukemia","volume":"27","author":"Atilla","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic Mechanisms of Target Antigen Loss in CAR19 Therapy of Acute Lymphoblastic Leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1182\/blood-2023-178954","article-title":"Low Target Antigen Expression Mediates Resistance to BCMA CAR T Cell Therapy","volume":"142","author":"Perica","year":"2023","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Bartoszewska, E., Tota, M., Kisielewska, M., Skowron, I., Sebastianka, K., Stefaniak, O., Molik, K., Rubin, J., Kraska, K., and Choroma\u0144ska, A. (2024). Overcoming Antigen Escape and T-Cell Exhaustion in CAR-T Therapy for Leukemia. Cells, 13.","DOI":"10.3390\/cells13181596"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41375-024-02351-2","article-title":"Rational Combinatorial Targeting by Adapter CAR-T-Cells (AdCAR-T) Prevents Antigen Escape in Acute Myeloid Leukemia","volume":"38","author":"Atar","year":"2024","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Atilla, E., and Benabdellah, K. (2023). The Black Hole: CAR T Cell Therapy in AML. Cancers, 15.","DOI":"10.20944\/preprints202304.0482.v1"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e18369","DOI":"10.1111\/jcmm.18369","article-title":"Recent Advances in CAR-T Cell Therapy for Acute Myeloid Leukaemia","volume":"28","author":"Gao","year":"2024","journal-title":"J. Cell. Mol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.1038\/cti.2016.73","article-title":"All-Trans Retinoic Acid Enhances Cytotoxic Effect of T Cells with an Anti-CD38 Chimeric Antigen Receptor in Acute Myeloid Leukemia","volume":"5","author":"Yoshida","year":"2016","journal-title":"Clin. Transl. Immunol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating Therapy Increases Anti-CD123 CAR T Cell Cytotoxicity against Acute Myeloid Leukemia","volume":"12","author":"Hughes","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Zarychta, J., Kowalczyk, A., Krawczyk, M., Lejman, M., and Zawitkowska, J. (2023). CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia-Recent Advances. Cancers, 15.","DOI":"10.3390\/cancers15112944"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40164-024-00561-z","article-title":"Natural Killer Cell-Based Cancer Immunotherapy: From Basics to Clinical Trials","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK Cell-Cancer Cycle: Advances and New Challenges in NK Cell-Based Immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat. Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Guijarro-Albaladejo, B., Marrero-Cepeda, C., Rodr\u00edguez-Arbol\u00ed, E., Sierro-Mart\u00ednez, B., P\u00e9rez-Sim\u00f3n, J.A., and Garc\u00eda-Guerrero, E. (2024). Chimeric Antigen Receptor (CAR) Modified T Cells in Acute Myeloid Leukemia: Limitations and Expectations. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1376554"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-024-00592-6","article-title":"Safety and Efficacy of CD33-Targeted CAR-NK Cell Therapy for Relapsed\/Refractory AML: Preclinical Evaluation and Phase I Trial","volume":"14","author":"Huang","year":"2025","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_97","first-page":"1083","article-title":"First-in-Man Clinical Trial of CAR NK-92 Cells: Safety Test of CD33-CAR NK-92 Cells in Patients with Relapsed and Refractory Acute Myeloid Leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Mardiana, S., and Gill, S. (2020). CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00697"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2248826","DOI":"10.1080\/2162402X.2023.2248826","article-title":"CAR-T Cells Dual-Target CD123 and NKG2DLs to Eradicate AML Cells and Selectively Target Immunosuppressive Cells","volume":"12","author":"Jin","year":"2023","journal-title":"Oncoimmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1007\/s11095-024-03761-8","article-title":"Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome","volume":"41","author":"Gandhi","year":"2024","journal-title":"Pharm. Res."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Epperly, R., Gottschalk, S., and Velasquez, M.P. (2020). A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00262"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1182\/bloodadvances.2020001797","article-title":"Lingering Effects of Chemotherapy on Mature T Cells Impair Proliferation","volume":"4","author":"Das","year":"2020","journal-title":"Blood Adv."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"72.e1","DOI":"10.1016\/j.jtct.2021.11.014","article-title":"Impact of Bridging Chemotherapy on Clinical Outcomes of CD19-Specific CAR T Cell Therapy in Children\/Young Adults with Relapsed\/Refractory B Cell Acute Lymphoblastic Leukemia","volume":"28","author":"Shahid","year":"2022","journal-title":"Transpl. Cell Ther."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e161","DOI":"10.1016\/S2352-3026(23)00002-9","article-title":"Taking a Step Forward in CAR T-Cell Therapy for Acute Myeloid Leukaemia and Myelodysplastic Syndrome","volume":"10","author":"Chua","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Lickefett, B., Chu, L., Ortiz-Maldonado, V., Warmuth, L., Barba, P., Doglio, M., Henderson, D., Hudecek, M., Kremer, A., and Markman, J. (2023). Lymphodepletion-an Essential but Undervalued Part of the Chimeric Antigen Receptor T-Cell Therapy Cycle. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1303935"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"11978","DOI":"10.1073\/pnas.1819992116","article-title":"Gene-Edited Stem Cells Enable CD33-Directed Immune Therapy for Myeloid Malignancies","volume":"116","author":"Borot","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"eadi1145","DOI":"10.1126\/scitranslmed.adi1145","article-title":"Epitope Base Editing CD45 in Hematopoietic Cells Enables Universal Blood Cancer Immune Therapy","volume":"15","author":"Wellhausen","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2024-194359","article-title":"Potent and Effective Targeting of AML with \u2018Off-the-Shelf\u2019 Engineered CD45-Targeting CAR T-Cells","volume":"144","author":"Shaw","year":"2024","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.ymthe.2020.10.008","article-title":"Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7","volume":"29","author":"Amatya","year":"2021","journal-title":"Mol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.omto.2020.04.009","article-title":"Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia","volume":"17","author":"Loff","year":"2020","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1182\/blood.2020009759","article-title":"Proof of Concept for a Rapidly Switchable Universal CAR-T Platform with UniCAR-T-CD123 in Relapsed\/Refractory AML","volume":"137","author":"Wermke","year":"2021","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Caldwell, K.J., Gottschalk, S., and Talleur, A.C. (2020). Allogeneic CAR Cell Therapy-More Than a Pipe Dream. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.618427"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40164-023-00435-w","article-title":"Current Approaches to Develop \u201coff-the-Shelf\u201d Chimeric Antigen Receptor (CAR)-T Cells for Cancer Treatment: A Systematic Review","volume":"12","author":"Aparicio","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Cao, X., Zhang, J., Zhao, Y., Xiong, M., Zhou, J., Lu, Y., Sun, R., Wei, Z., Liu, D., and Zhang, X. (2023). Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in Patients with Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after Transplant. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1191382"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:44:06Z","timestamp":1760031846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":114,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060322"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060322","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}